British Association of Dermatologists

Vulva health conditions: it's time to shatter the silence

Retrieved on: 
Tuesday, September 5, 2023

I didn’t know I had a vulva until I was diagnosed with lichen sclerosus and stage three vulval cancer.

Key Points: 
  • I didn’t know I had a vulva until I was diagnosed with lichen sclerosus and stage three vulval cancer.
  • She spoke of her anger at how, despite numerous doctor appointments, her cancer was not spotted until it was at an advanced stage.
  • Baumhauer had had symptoms since the age of five, feeling burning pain “like razor blades” when going to the toilet.
  • Despite undergoing 58 rounds of radiotherapy in 2016- 2017, Baumhauer experienced a recurrence in 2023 and had to have further surgery.

A disturbing silence

    • There are accounts of women experiencing dyspareunia (pain during sex) in ancient Egyptian papyri.
    • Yet today there is still an oppressive silence around the vulva and vulval disease.
    • This article is part of Women’s Health Matters, a series about the health and wellbeing of women and girls around the world.
    • So young women and those who menstruate grow up thinking gynaecological pain is just something to be accepted, even expected.
    • Instead, we receive the message that we shouldn’t be surprised when we experience pain or itching, but we also shouldn’t talk about it.

Breaking the silence

    • In the 1970s and 1980s, women began to break the silence and share their breast cancer experiences with the public.
    • The disease claims tens of thousands of lives a year, but a silence surrounded it meaning many missed the early signs.
    • And recently singer Meghan Trainor shared her experience of vaginismus, a condition causing the pelvic muscles to tense up painfully during sex.
    • Visual, literary and performing arts can be powerful tools for breaking down stigma.

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

Retrieved on: 
Monday, March 20, 2023

BASKING RIDGE, NJ, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the online publication of a sub-analysis of the Phase 2b CONTROL study in Clinical and Experimental Dermatology (CED), the educational journal of the British Association of Dermatologists. The CONTROL study evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in subjects nine years of age and older with moderate to severe congenital ichthyosis (CI).

Key Points: 
  • The CONTROL study evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in subjects nine years of age and older with moderate to severe congenital ichthyosis (CI).
  • CI is a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin.
  • “In this sub-analysis, participants in the CONTROL study with ARCI and XLRI mostly showed comparable percentage differences in responses to treatment with a novel topical isotretinoin formulation versus vehicle.
  • The intent-to-treat (ITT) population consisted of all randomized participants who received one or more doses of the study medication.

Retinol (Vitamin A) Global Market Report 2022: Excellent Pharmacodynamic and Pharmacokinetic Effects Propels Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022

The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Natural retinol is obtained from sources such as sweet potatoes, carrots, apricots, oranges, eggs, meat and dairy products.
  • They are present in very small quantities in daily dietary intake which led to the demand for synthetic retinol.
  • The factors responsible for their increasing demand are excellent pharmacodynamic and pharmacokinetic properties possessed by synthetic retinol.

LEO Pharma Announces British Journal of Dermatology Publication of Adbry™ (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Wednesday, October 26, 2022

Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.

Key Points: 
  • Our ongoing clinical program continues to reveal new learnings and insights on the safety profile of Adbry.
  • Safety remains a top priority for people with moderate-to-severe atopic dermatitis and the clinicians who treat them, as well as for LEO Pharma.
  • Adbry is approved for adult patients whose disease is not adequately controlled with topical prescription therapies or when those are not advisable.
  • The British Journal of Dermatology is owned by British Association of Dermatologists (BAD), the central association of practising UK dermatologists.